[Studies of combined treatment of radiofrequency hyperthermia with anticancer agents or irradiation for invasive bladder cancer].
Using an in vitro colony forming assay system, the cytotoxic effects of anticancer agents alone, adriamycin (ADM) and bleomycin (BLM), and the combined effects of hyperthermia and anticancer agents on cultivated KK-47 cells were investigated. When the hyperthermia was combined with various concentrations of ADM ranging from 0.005 to 0.1 microgram/ml and BLM from 0.01 to 1.0 microgram/ml, enhanced cell killing effects were obtained at the concentration of less than 0.02 microgram/ml of ADM and with an increase of BLM concentration. In DNA specimens obtained from the livers of chick embryos inoculated with human tumor cultivated cells, the polymerase chain reaction technique was used to amplify a DNA fragment specific to the beta-globin gene. By detecting these amplified DNA fragments, the feasibility of efficiently detecting metastatic cells present in chick embryo was demonstrated in vivo. Hyperthermic therapy showed inhibitory effects on the growth of metastasized cultivated cells in a thermal dose-dependent manner. Combination therapy of ADM, mitomycin and carboplatin and hyperthermia had an enhanced inhibitory activity on the growth of metastasized cultivated human tumor cells derived from bladder cancer. Hyperthermia using radiofrequency-capacitive heating in combination with irradiation or anticancer agents, was performed in a total of 56 patients with T2 to T4 invasive urinary bladder cancer. A tumor regression rate of 50 percent or more was obtained in 21 of these 56 patients. We have to follow up the patients for longer periods more precisely to evaluate the role of these treatments.
Uchibayashi
T
T
Department of Urology, School of Medicine, Kanazawa University.
Lee
S W
SW
Hisazumi
H
H
Naito
K
K
Endo
Y
Y
Noguchi
M
M
Tanaka
M
M
Sasaki
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001761:Bleomycin / Q000008:administration & dosage*; D002642:Chick Embryo; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D014407:Tumor Cells, Cultured / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*
D001761:Bleomycin; D004317:Doxorubicin